Key studies to be presented at the 11th IAS Conference on HIV Science, from International Co-Chair and IAS President, Dr. Adeeba Kamarulzaman
Not sure how to interpret conflicting results in studies of HIV and SARS-CoV-2 coinfection? Dr. Daniel R. Kuritzkes discusses new results of studies of people with HIV and COVID-19, presented at IAS 2021.
Listen to expert insights from Babafemi Taiwo, MBBS, on updates from IAS 2021, including new data on COVID-19 and HIV, 2-drug ART, long-acting injectable ART, investigational agents, and new therapies for multidrug-resistant tuberculosis.
Hear insights from Jennifer Cocohoba, PharmD, and Jason Schafer, PharmD, MPH, on exciting new data from IAS 2021, including 2-drug regimens for ART, long-acting ART, and novel antiretrovirals, and learn how these new data influence the role of the pharmacist in caring for patients with HIV.
Read expert faculty members’ summaries of key studies from this important annual conference, including new data on the following hot topics: HIV PrEP; 2-drug regimen ART; ART in children and adolescents; long-acting ART; investigational ART; treatment strategies for cryptococcal meningitis and drug resistant tuberculosis; and COVID-19 outcomes in people with HIV.
Hear unique insights from CCO’s expert faculty, Dr. Chloe Orkin, as she presents her insights on some of the most clinically relevant new data presented at IAS 2021, including results from studies on HIV and COVID-19 outcomes; virologic and metabolic outcomes of DTG/3TC; long-acting CAB + RPV for ART in treatment-naive PWH; investigational antiretroviral agents, lenacapavir and islatravir; and alternative dosing of BPaL for MDR-TB.
Hear unique insights from CCO’s expert faculty, Dr. Daniel Kuritzkes, as he presents his insights on some of the most clinically relevant new data presented at IAS 2021, including results from studies on HIV and COVID-19 outcomes; virologic and metabolic outcomes of DTG/3TC; long-acting CAB + RPV for ART in treatment-naive PWH; investigational antiretroviral agents, lenacapavir and islatravir; and alternative dosing of BPaL for MDR-TB.
Hear unique insights from CCO’s expert faculty, Dr. Babafemi Taiwo, as he presents his insights on some of the most clinically relevant new data presented at IAS 2021, including results from studies on HIV and COVID-19 outcomes; virologic and metabolic outcomes of DTG/3TC; long-acting CAB + RPV for ART in treatment-naive PWH; investigational antiretroviral agents, lenacapavir and islatravir; and alternative dosing of BPaL for MDR-TB.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.